Literature DB >> 7853786

Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats.

M Gellai1, R DeWolf, M Pullen, P Nambi.   

Abstract

Experiments were designed to compare the distribution and physiological roles of endothelin (ET) receptor subtypes, ETA and ETB, in the kidneys of normotensive Sprague-Dawley (SD) and spontaneously hypertensive (SH) rats. Using [125I] ET-1 and subtype-selective ligands sarafotoxin 6c (S6c, ETB-selective agonist) and BQ123 (ETA-selective antagonist), the distribution of ETA and ETB receptors in SD rat kidney cortex, outer medulla and papilla was calculated to be 50:50, 30:70 and 10:90, respectively. The ET receptor subtypes in outer medulla and papilla of age-matched SH rats were similar to those of SD. However, in the cortex of SH rats, the ratio of ETA to ETB was 25:75 compared to 50:50 in SD rats. In addition, the affinity of the ET receptors was also higher in SH rats (117 pM vs. 235 pM). In the conscious SD rats, bolus i.v. injections of ET-1 and S6c elicited similar dose-dependent decrease in renal blood flow (RBF), which were unaffected by the infusion of the selective ETA receptor antagonist, BQ123. The SH rats were more sensitive to the renal vasoconstrictor effect of S6c and ET-1. Also, the dose-response curve to S6c was shifted to the left when compared to ET-1; however, BQ123 infusion abolished this difference. In renal clearance studies, BQ123 infusions decreased RBF and glomerular filtration rate (GFR) only in SH rats, and the fractional excretion of sodium only in SD rats. The combined data indicate that the distribution and functional roles of ETA and ETB receptor subtypes are altered in the kidneys of SH rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853786     DOI: 10.1038/ki.1994.396

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  High salt intake increases endothelin B receptor function in the renal medulla of rats.

Authors:  Chunhua Jin; Joshua S Speed; David M Pollock
Journal:  Life Sci       Date:  2015-12-24       Impact factor: 5.037

Review 5.  Endothelin and the renal microcirculation.

Authors:  Zhengrong Guan; Justin P VanBeusecum; Edward W Inscho
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

6.  Decrease in endothelin-1 renal receptors during the 1st month of life in the rat.

Authors:  L Abadie; I Blazy; P Roubert; P Plas; M Charbit; P E Chabrier; M Dechaux
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

7.  Influence of endothelins and sarafotoxin 6c and L-NAME on renal vasoconstriction in the anaesthetized rat.

Authors:  J L Marshall; E J Johns
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

8.  Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension.

Authors:  B Hocher; C Thöne-Reineke; P Rohmeiss; F Schmager; T Slowinski; V Burst; F Siegmund; T Quertermous; C Bauer; H H Neumayer; W D Schleuning; F Theuring
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

9.  Endothelin as a causative factor of blunted volume reflex in diabetic rats.

Authors:  Orawan Wongmekiat; Edward J Johns
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

10.  Paracrine renal endothelin system in rats with liver cirrhosis.

Authors:  B Hocher; R Zart; F Diekmann; P Rohmeiss; A Distler; H H Neumayer; C Bauer; P Gross
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.